Evaluation of implementation of evolving practice patterns in the first-line treatment of patients with metastatic non-small cell lung cancer in Turkiye (ESTIMATE): a national, multicenter, retrospective, real-world evidence study

ŞENDUR M. A. N., Karadurmus N., Cicin I., GÜMÜŞ M., Demirci U., Ozyilkan O., ...Daha Fazla

FUTURE ONCOLOGY, cilt.21, sa.19, ss.2525-2535, 2025 (SCI-Expanded, Scopus) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 21 Sayı: 19
  • Basım Tarihi: 2025
  • Doi Numarası: 10.1080/14796694.2025.2527477
  • Dergi Adı: FUTURE ONCOLOGY
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, CINAHL, EMBASE, MEDLINE
  • Sayfa Sayıları: ss.2525-2535
  • Karadeniz Teknik Üniversitesi Adresli: Evet

Özet

BackgroundThis national, multicenter, retrospective, non-interventional real-world evidence study aimed to address patient characteristics and systemic treatment practices of metastatic non-small cell lung cancer (mNSCLC) patients in T & uuml;rkiye.Research design and methodsOver 6 months, 636 adults with mNSCLC at 12 Turkish oncology centers provided retrospective data.ResultsAdenocarcinoma was the most common histology, with 95% having distant bone metastases and 64.8% having no comorbidities. The most frequently administered first-line therapy was combination chemotherapy followed by targeted therapy and immunotherapy. Overall, 55.5-69.3% of patients were tested for ALK, EGFR, ROS1, and PD-L1.ConclusionsBiomarker screening in mNSCLC patients in T & uuml;rkiye was suboptimal compared to other countries, especially in public hospitals.